News about Global Pharma

Valo Health and Novo Nordisk to Develop Novel Treatments for Cardiometabolic Diseases

The expanded collaboration will continue to leverage the capabilities of Valo’s Opal Computational Platform, as well as key joint capabilities in human data and genetics with Novo Nordisk’s expertise in cardiometabolic diseases.

Global Pharma | 09/01/2025 | By Aishwarya |  575

Antag Therapeutics Names Dr. Joerg Moeller as its Chief Executive Officer

With over 30 years of industry and leadership experience, Dr. Moeller has an impressive track record of successfully leading large global organizations and has built an expansive portfolio by driving strategic growth, regulatory compliance, and fostering innovation.

Global Pharma | 09/01/2025 | By Aishwarya |  201

NorthStar and YAP Therapeutics to Develop and Manufacture Radiopharmaceutical Products

Within this collaboration, NorthStar will support the development of YAP Therapeutics' biologic products by supplying the radioisotope non-carrier added actinium-225 (n.c.a. Ac-225) and providing access to its radiopharmaceutical contract development and manufacturing (CDMO) services.

Global Pharma | 09/01/2025 | By Aishwarya |  530

BlackfinBio Acquires Parkinson's IP Patent Portfolio from OXB

BlackfinBio Ltd (BFB), a clinical-stage gene therapy company, has acquired the Parkinson's patent portfolio from OXB to develop as part of its BFB-201 program targeting dopamine deficiency diseases.

Global Pharma | 08/01/2025 | By Manvi |  148

Orna Therapeutics and Vertex Pharmaceuticals Partner on Next-Gen Therapies for SCD and TDT

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, has entered a three-year collaboration with Vertex Pharmaceuticals to leverage its proprietary LNP delivery technology for next-generation gene-editing therapies targeting SCD and TDT.

Global Pharma | 08/01/2025 | By Manvi |  769

ProBioGen Expands Protein and Viral Manufacturing in Berlin Plant

In the protein vertical, this strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development through to commercial manufacturing.

Global Pharma | 08/01/2025 | By Aishwarya |  258

ASPA Announces to Host Sixth Edition of TAF 2025

TAF 2025, themed ‘Path to a Secure Future – Authentication and Traceability for All’, is recognized as a premier global platform for tackling challenges related to counterfeiting, traceability, and brand protection.

Global Pharma | 08/01/2025 | By Aishwarya |  728

Phillips Medisize Expands its Inhalation Drug Delivery Capabilities

With the addition of Vectura, the company now offers a wider range of formulation, device design, combination product development and manufacturing services.

Global Pharma | 08/01/2025 | By Aishwarya |  352

Dizal's Sunvozertinib Receives FDA Priority Review for EGFR-Mutated NSCLC Treatment

Dizal's Sunvozertinib, an oral EGFR inhibitor for advanced NSCLC with EGFR exon20ins mutations, receives FDA priority review, marking a milestone in addressing unmet needs in cancer treatment.

Global Pharma | 07/01/2025 | By Manvi |  375

Sentynl Therapeutics' CUTX-101 for Menkes Disease Gets FDA Priority Review

Sentynl Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted for filing and priority review of Sentynl’s New Drug Application (NDA) for CUTX-101, the product candidate for the treatment of Menkes disease.

Global Pharma | 07/01/2025 | By Manvi |  507